{"id":15288,"date":"2024-02-08T08:45:38","date_gmt":"2024-02-08T07:45:38","guid":{"rendered":"https:\/\/www.ifpma.org\/?post_type=publications&p=15288"},"modified":"2024-03-14T10:48:12","modified_gmt":"2024-03-14T09:48:12","slug":"regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future","status":"publish","type":"publications","link":"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/","title":{"rendered":"Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future"},"content":{"rendered":"

During the COVID-19 pandemic, National Regulatory Authorities (NRAs) and the biopharmaceutical industry applied a variety of regulatory agilities to accelerate the development, evaluation, authorization, and supply of COVID-19 vaccines. These agilities were a key factor in enabling rapid patient access to vaccines.<\/p>\n

Experience from the pandemic and the use of regulatory agilities offers valuable insights on how regulatory systems may be adapted to further support innovation and timely patient access to vaccines at all times, not just during emergencies.<\/p>\n

This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.<\/p>\n","protected":false},"excerpt":{"rendered":"

This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.<\/p>\n","protected":false},"featured_media":15299,"template":"","publication_type":[7],"topic":[26],"class_list":["post-15288","publications","type-publications","status-publish","has-post-thumbnail","hentry","publication_type-position-paper","topic-regulatory-convergence-and-reliance"],"acf":[],"yoast_head":"\nRegulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future | IFPMA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future | IFPMA\" \/>\n<meta property=\"og:description\" content=\"This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/\" \/>\n<meta property=\"og:site_name\" content=\"IFPMA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IFPMA\/\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-14T09:48:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/02\/Regulatory-agilities_Position-paper_IFPMA_web.png\" \/>\n\t<meta property=\"og:image:width\" content=\"634\" \/>\n\t<meta property=\"og:image:height\" content=\"896\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@IFPMA\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/\",\"url\":\"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/\",\"name\":\"Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future | IFPMA\",\"isPartOf\":{\"@id\":\"https:\/\/www.ifpma.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/02\/Regulatory-agilities_Position-paper_IFPMA_web.png\",\"datePublished\":\"2024-02-08T07:45:38+00:00\",\"dateModified\":\"2024-03-14T09:48:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/#primaryimage\",\"url\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/02\/Regulatory-agilities_Position-paper_IFPMA_web.png\",\"contentUrl\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/02\/Regulatory-agilities_Position-paper_IFPMA_web.png\",\"width\":634,\"height\":896},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ifpma.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/www.ifpma.org\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ifpma.org\/#website\",\"url\":\"https:\/\/www.ifpma.org\/\",\"name\":\"IFPMA\",\"description\":\"Innovating to improve health worldwide\",\"publisher\":{\"@id\":\"https:\/\/www.ifpma.org\/#organization\"},\"alternateName\":\"International Federation of Pharmaceutical Manufacturers and Associations\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ifpma.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ifpma.org\/#organization\",\"name\":\"IFPMA\",\"alternateName\":\"International Federation of Pharmaceutical Manufacturers and Associations\",\"url\":\"https:\/\/www.ifpma.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png\",\"contentUrl\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png\",\"width\":1379,\"height\":733,\"caption\":\"IFPMA\"},\"image\":{\"@id\":\"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/IFPMA\/\",\"https:\/\/x.com\/IFPMA\",\"https:\/\/www.linkedin.com\/company\/ifpma\/\",\"https:\/\/www.youtube.com\/user\/ifpma\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future | IFPMA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/","og_locale":"en_US","og_type":"article","og_title":"Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future | IFPMA","og_description":"This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.","og_url":"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/","og_site_name":"IFPMA","article_publisher":"https:\/\/www.facebook.com\/IFPMA\/","article_modified_time":"2024-03-14T09:48:12+00:00","og_image":[{"width":634,"height":896,"url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/02\/Regulatory-agilities_Position-paper_IFPMA_web.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@IFPMA","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/","url":"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/","name":"Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future | IFPMA","isPartOf":{"@id":"https:\/\/www.ifpma.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/#primaryimage"},"image":{"@id":"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/02\/Regulatory-agilities_Position-paper_IFPMA_web.png","datePublished":"2024-02-08T07:45:38+00:00","dateModified":"2024-03-14T09:48:12+00:00","breadcrumb":{"@id":"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/#primaryimage","url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/02\/Regulatory-agilities_Position-paper_IFPMA_web.png","contentUrl":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/02\/Regulatory-agilities_Position-paper_IFPMA_web.png","width":634,"height":896},{"@type":"BreadcrumbList","@id":"https:\/\/www.ifpma.org\/publications\/regulatory-agilities-applied-to-vaccines-during-the-covid-19-pandemic-and-recommendations-for-the-future\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ifpma.org\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/www.ifpma.org\/publications\/"},{"@type":"ListItem","position":3,"name":"Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future"}]},{"@type":"WebSite","@id":"https:\/\/www.ifpma.org\/#website","url":"https:\/\/www.ifpma.org\/","name":"IFPMA","description":"Innovating to improve health worldwide","publisher":{"@id":"https:\/\/www.ifpma.org\/#organization"},"alternateName":"International Federation of Pharmaceutical Manufacturers and Associations","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ifpma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ifpma.org\/#organization","name":"IFPMA","alternateName":"International Federation of Pharmaceutical Manufacturers and Associations","url":"https:\/\/www.ifpma.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png","contentUrl":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png","width":1379,"height":733,"caption":"IFPMA"},"image":{"@id":"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/IFPMA\/","https:\/\/x.com\/IFPMA","https:\/\/www.linkedin.com\/company\/ifpma\/","https:\/\/www.youtube.com\/user\/ifpma"]}]}},"_links":{"self":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/publications\/15288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/publications"}],"about":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/types\/publications"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/media\/15299"}],"wp:attachment":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/media?parent=15288"}],"wp:term":[{"taxonomy":"publication_type","embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/publication_type?post=15288"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/topic?post=15288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}